E-LIB Suche - Ergebnisse für: Bachy, E

1

Long‐term efficacy and safety of zanubrutinib (ZANU) in rel..:

Trotman, J. ; Tedeschi, A. ; Hu, B....
Hematological Oncology. 41 (2023) S2 - p. 390-392 , 2023

Link: https://doi.org/10.1002/..

2

ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSL..:

Camus, V. ; Thieblemont, C. ; Gaulard, P....
Hematological Oncology. 41 (2023) S2 - p. 77-78 , 2023

Link: https://doi.org/10.1002/..

3

OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGAS..:

Michot, J. M. ; Chavez, J. ; Carpio, C....
Hematological Oncology. 41 (2023) S2 - p. 134-136 , 2023

Link: https://doi.org/10.1002/..

4

Cell‐free DNA sequencing allows the identification of the m..:

Sako, N. ; Delfau, M. ; Bachy, E....
Hematological Oncology. 41 (2023) S2 - p. 338-339 , 2023

Link: https://doi.org/10.1002/..

5

Functional precision oncology for follicular lymphoma with ..:

Zala, M. ; Lipinski, B. ; Costechareyre, C....
Hematological Oncology. 41 (2023) S2 - p. 549-549 , 2023

Link: https://doi.org/10.1002/..

6

EARLY CTDNA CLEARANCE AFTER CAR T‐CELL INFUSION PREDICTS OU..:

Delfau‐Larue, M. ; Viailly, P. ; Cartron, G....
Hematological Oncology. 41 (2023) S2 - p. 179-181 , 2023

Link: https://doi.org/10.1002/..

7

Transfusion needs after CD19 CAR T‐cells for large B‐cell l..:

Vic, S. ; Thibert, J. ; Bachy, E....
Hematological Oncology. 41 (2023) S2 - p. 534-536 , 2023

Link: https://doi.org/10.1002/..

8

A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD2..:

Mozas, P. ; Ammar, R. Ould ; Chartier, L....
Hematological Oncology. 41 (2023) S2 - p. 290-291 , 2023

Link: https://doi.org/10.1002/..

9

KILT: A RANDOMIZED NON‐COMPARATIVE PHASE II LYSA STUDY OF L..:

Cheminant, M. ; Carras, S. ; Bruneau, J....
Hematological Oncology. 41 (2023) S2 - p. 838-839 , 2023

Link: https://doi.org/10.1002/..

10

CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY FOLLICULAR HE..:

Loyaux, R. ; Sako, N. ; Quang, V. Tran...
Hematological Oncology. 41 (2023) S2 - p. 108-110 , 2023

Link: https://doi.org/10.1002/..

11

RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES ..:

Rebaud, L. ; Capobianco, N. ; Spottiswoode, B....
Hematological Oncology. 41 (2023) S2 - p. 94-95 , 2023

Link: https://doi.org/10.1002/..

12

PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIB..:

Hertzberg, M. ; Kalac, M. ; Cheah, C. Y....
Hematological Oncology. 41 (2023) S2 - p. 131-132 , 2023

Link: https://doi.org/10.1002/..

13

TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTI..:

Cho, S. ; Kim, T. M. ; Taszner, M....
Hematological Oncology. 41 (2023) S2 - p. 846-847 , 2023

Link: https://doi.org/10.1002/..

14

AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐..:

Houot, R. ; Bachy, E. ; Cartron, G....
Hematological Oncology. 41 (2023) S2 - p. 147-148 , 2023

Link: https://doi.org/10.1002/..

15

GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY..:

Dickinson, M. ; Carlo‐Stella, C. ; Morschhauser, F....
Hematological Oncology. 41 (2023) S2 - p. 144-146 , 2023

Link: https://doi.org/10.1002/..